
Screening phase.

haplo-SCT, neuroblastoma, Neuroblastoma
NEUROBLASTOMA, NEUROBLASTOMA, APPENDIX
This study was a prospective single-arm open-label phase I/II trial. Eligibility criteria were (1) age 1-21 years at trial enrollment, (2) relapsed/refractory International Neuroblastoma Staging System stage 4 neuroblastoma or relapsed The trial protocol did not make recommendations on systemic chemotherapy and local treatment before haplo-SCT (Data Supplement [Appendix 1]). At the discretion of the treating centers, 